| [1] |
Noticewala SS, Das P. Current state of neoadjuvant therapy for locally advanced rectal cancer[J]. Cancer J, 2024, 30(4): 227-231. DOI: 10.1097/PPO.0000000000000725.
pmid: 39042772
|
| [2] |
Body A, Prenen H, Lam M, et al. Neoadjuvant therapy for locally advanced rectal cancer: recent advances and ongoing challenges[J]. Clin Colorectal Cancer, 2021, 20(1): 29-41. DOI: 10.1016/j.clcc.2020.12.005.
|
| [3] |
Tokuhara K, Matsui Y, Ueyama Y, et al. Feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer[J]. J Anus Rectum Colon, 2022, 6(1): 24-31. DOI: 10.23922/jarc.2021-033.
pmid: 35128134
|
| [4] |
Liu Z, Meng R, Ma Q, et al. Predicting recurrence in locally advanced rectal cancer using multitask deep learning and multimodal MRI[J]. Radiol Imaging Cancer, 2025, 7(3): e240359. DOI: 10.1148/rycan.240359.
|
| [5] |
Schurink NW, van Kranen SR, Berbee M, et al. Studying local tumour heterogeneity on MRI and FDG-PET/CT to predict response to neo-adjuvant chemoradiotherapy in rectal cancer[J]. Eur Radiol, 2021, 31(9): 7031-7038. DOI: 10.1007/s00330-021-07724-0.
pmid: 33569624
|
| [6] |
中华人民共和国卫生和计划生育委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017年版)[J]. 中华外科杂志, 2018, 56(4): 241-258. DOI: 10.3760/cma.j.issn.0529-5815.2018.04.001.
|
| [7] |
Kim SH, Chang HJ, Kim DY, et al. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy[J]. Cancer Res Treat, 2016, 48(3): 998-1009. DOI: 10.4143/crt.2015.254.
|
| [8] |
Li N, Zhu Y, Liu L, et al. Postoperative chemoradiotherapy with capecitabine and oxaliplatin vs. capecitabine for pathological stage N2 rectal cancer[J]. Chin J Cancer Res, 2024, 36(5): 577-586. DOI: 10.21147/j.issn.1000-9604.2024.05.09.
|
| [9] |
Tang M, Liu S, Li W, et al. Prognostic value of albumin-to-alkaline phosphatase ratio and CONUT score in rectal cancer patients under-going XELOX-based chemotherapy: development of a nomogram-based predictive model[J]. Am J Cancer Res, 2025, 15(4): 1578-1596. DOI: 10.62347/HSDE2538.
pmid: 40371163
|
| [10] |
Liu Z, Jia J, Bai F, et al. Predicting rectal cancer tumor budding grading based on MRI and CT with multimodal deep transfer learning: a dual-center study[J]. Heliyon, 2024, 10(7): e28769. DOI: 10.1016/j.heliyon.2024.e28769.
|
| [11] |
Shin J, Seo N, Baek SE, et al. MRI radiomics model predicts pathologic complete response of rectal cancer following chemoradiotherapy[J]. Radiology, 2022, 303(2): 351-358. DOI: 10.1148/radiol.211986.
pmid: 35133200
|
| [12] |
Jiménez de Los Santos ME, Reyes-Pérez JA, Domínguez Osorio V, et al. Whole lesion histogram analysis of apparent diffusion coefficient predicts therapy response in locally advanced rectal cancer[J]. World J Gastroenterol, 2022, 28(23): 2609-2624. DOI: 10.3748/wjg.v28.i23.2609.
|
| [13] |
冯涛, 许双燕, 刘洋洋, 等. 3.0T多模态MRI评估直肠癌T分期及新辅助治疗效果[J]. 中国医学影像技术, 2023, 39(12): 1877-1882. DOI: 10.13929/j.issn.1003-3289.2023.12.031.
|
| [14] |
Amodeo S, Rosman AS, Desiato V, et al. MRI-based apparent diffusion coefficient for predicting pathologic response of rectal cancer after neoadjuvant therapy: systematic review and meta-analysis[J]. AJR Am J Roentgenol, 2018, 211(5): 205-216. DOI: 10.2214/AJR.17.19135.
|
| [15] |
Pham TT, Lim S, Lin M. Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer[J]. Expert Rev Anticancer Ther, 2022, 22(10): 1081-1098. DOI: 10.1080/14737140.2022.2114457.
|
| [16] |
Kim HR, Kim SH, Nam KH. Association between dynamic contrast-enhanced MRI parameters and prognostic factors in patients with primary rectal cancer[J]. Curr Oncol, 2023, 30(2): 2543-2554. DOI: 10.3390/curroncol30020194.
pmid: 36826155
|
| [17] |
许文森, 柳永康, 苗环, 等. MR扩散加权成像与动态对比增强MRI评价局部进展期直肠癌新辅助放化疗疗效的价值[J]. 实用放射学杂志, 2023, 39(11): 1801-1805, 1814. DOI: 10.3969/j.issn.1002-1671.2023.11.015.
|
| [18] |
El Homsi M, Yildirim O, Gangai N, et al. Contrast-enhanced pelvic magnetic resonance imaging (MRI) for the prediction of treatment response in mucinous rectal cancer[J]. Quant Imaging Med Surg, 2024, 14(6): 4110-4122. DOI: 10.21037/qims-23-1463.
|
| [19] |
Wang Q, Zhang XY, Yang JF, et al. Comparison of dynamic contrast-enhanced-magnetic resonance imaging parameters and serum markers in preoperative rectal cancer evaluation: combined diagnostic value[J]. World J Gastrointest Oncol, 2025, 17(5): 103809. DOI: 10.4251/wjgo.v17.i5.103809.
|
| [20] |
吕霞, 刘强, 刘岘, 等. 直肠癌DCE-MRI定量参数与病理分化程度和p53的相关性[J]. 实用医学杂志, 2022, 38(4): 479-483. DOI: 10.3969/j.issn.1006-5725.2022.04.016.
|
| [21] |
Zhao K, Li H, Pang W, et al. Influence of high-risk pathological factors and their interaction on the survival benefit of adjuvant chemotherapy in stage Ⅱ rectal cancer: a retrospective study[J]. J Cancer, 2024, 15(11): 3531-3538. DOI: 10.7150/jca.95769.
|
| [22] |
Wu SJ, Wu CY, Ye K. Risk factors, monitoring, and treatment strategies for early recurrence after rectal cancer surgery[J]. World J Gastrointest Surg, 2025, 17(1):100232. DOI: 10.4240/wjgs.v17.i1.100232.
|